Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Statins and diabetes.

2005

Lipid abnormalities play an important part in raising the cardiovascular risk in diabetic subjects. The main components of diabetic dyslipidemia are increased plasma triglycerides, low concentration of high-density lipoprotein cholesterol, preponderance of small, dense low-density lipoprotein, and excessive postprandial lipemia. Small, dense low-density lipoprotein, the elevation in remnant triglyceride-rich lipoprotein particles, and the low high-density lipoprotein are the most powerful atherogenic components. The coexistence of these three factors strongly aggravates the lipid accumulation in the arterial wall and the formation of atherosclerotic plaques. The position of diabetes in card…

medicine.medical_specialtyVery low-density lipoproteinHyperlipidemiasType 2 diabeteschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansTriglyceridebusiness.industrymedicine.diseaseLipidsEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Therapeutic Lifestyle ChangesMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLipoproteinSeminars in vascular medicine
researchProduct

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms

2001

To induce atherogenesis in mice, a high fat (HF) diet is supplemented with cholic acid (CA), which increases apoB-containing particles and lower apoA-I-containing particles. HF diet without CA increases levels of both HDL and LDL, suggesting that CA may be responsible for the elevation of LDL and lowering of HDL. The mechanism of dietary CA-induced lowering of apoA-I-containing particles has recently been reported. In this study, we examined the mechanism of CA- and HF-induced elevation of apoB-containing lipoproteins in mice. Mice were fed the following four diets: control chow (C), high fat high cholesterol, (HF), control and 0.5% cholate (CA), and HF + CA. Dietary CA increased the plasma…

medicine.medical_specialtyVery low-density lipoproteinSettore MED/09 - Medicina InternaMouseApolipoprotein Bmedicine.medical_treatmentDown-RegulationCholic AcidLipoproteins VLDLBiochemistryDietary cholateMicechemistry.chemical_compoundApolipoproteins ERibonucleasesDownregulation and upregulationInternal medicinemedicineAnimalsVitamin ERNA MessengerRNA Processing Post-TranscriptionalReceptorApolipoproteins BbiologyChemistryVitamin ECholic acidnutritional and metabolic diseasesCell BiologyBlotting NorthernDietLipoproteins LDLMice Inbred C57BLCholesterolEndocrinologyLiverReceptors LDLLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Gene expressionHepatic lipaseApolipoprotein BCholatesDietary fatThe International Journal of Biochemistry & Cell Biology
researchProduct

Statins and metabolic syndrome

2003

Abstract Metabolic syndrome (MS) is a multifactorial condition that represents a risk factor for the development of diabetes mellitus (DMII) and cardiovascular disease (CVD). Statins may play a role on some modifiable clinical features of MS; in fact, whereas therapeutic lifestyle changes are mandatory for MS with a 10-year coronary heart disease (CHD) risk 20% and to correct the other associated lipid and non-lipid abnormalities. In fact, they have a VLDL lowering action in hypertriglyceridemia, they reduce the amount of small and dense LDL, they increase the HDL-C, they reduce the atherogenic lipoproteins, and they decrease the inflammatory marker levels.

medicine.medical_specialtyVery low-density lipoproteinbusiness.industryHypertriglyceridemianutritional and metabolic diseasesGeneral MedicineDiseasemedicine.diseaseEndocrinologyDiabetes mellitusInternal medicinemedicineCardiologylipids (amino acids peptides and proteins)RosuvastatinTherapeutic Lifestyle ChangesMetabolic syndromeRisk factorbusinessmedicine.drugInternational Congress Series
researchProduct

Postprandial triglyceridaemia is modulated by insulin resistance but not by grade of obesity in abdominal and morbid obese subjects

2020

Background Obesity is associated with high cardiovascular risk. Postprandial lipidaemia has been associated with cardiovascular disease risk. Our aim was to identify whether anthropometric parameters, insulin resistance (IR) and/or fasting plasma triglycerides may determine postprandial changes in lipoprotein concentrations in abdominal and morbid obese subjects. Methods We have studied 20 non-diabetic, normolipidaemic subjects with abdominal obesity, 20 morbid obese subjects and 20 healthy individuals, that have similar age and gender. In all of them a standardised oral fat load test (OFLT) with unsaturated fat was performed. Results During the OFLT, the postprandial triglycerides response…

medicine.medical_specialtyWaist030204 cardiovascular system & hematologyGastroenterologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceInternal medicinemedicineHumansInsulin030212 general & internal medicineTriglyceridesAbdominal obesitybusiness.industryUnsaturated fatGeneral MedicinePostprandial Periodmedicine.diseaseObesityObesity MorbidPostprandialchemistryObese subjectsInsulin Resistancemedicine.symptombusinessLipoproteinInternational Journal of Clinical Practice
researchProduct

Both poor cardiorespiratory and weak muscle fitness are related to a high concentration of oxidized low-density lipoprotein lipids

2011

Good physical fitness is associated with favorable serum lipids. Oxidized low-density lipoprotein (ox-LDL) could be even more atherogenic than serum lipids. We studied the association of ox-LDL and serum lipids with physical fitness. Healthy young (mean age 25 years) men (n=846) underwent maximal oxygen uptake (VO(2max)) and muscle fitness index (MFI) tests and completed a leisure-time physical activity (LTPA) questionnaire. Age (ANCOVA1), age+waist circumference+systolic blood pressure+fasting blood glucose+smoking (ANCOVA3) were used as covariates. The groups with the lowest VO(2max), MFI and LTPA had 23%, 16% and 8% higher concentrations of ox-LDL than the groups with the highest VO(2max…

medicine.medical_specialtyWaistbusiness.industryPhysical fitnessOxidized low density lipoproteinBlood lipidsVO2 maxPhysical Therapy Sports Therapy and RehabilitationCardiorespiratory fitnessEndocrinologyBlood pressureInternal medicinemedicinelipids (amino acids peptides and proteins)Orthopedics and Sports MedicinebusinessLipoproteinScandinavian Journal of Medicine & Science in Sports
researchProduct

THE ATHEROGENIC LIPOPROTEIN PHENOTYPE AS PREDICTOR OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON-CORONARY FORMS OF ATHEROSCLEROSIS

2008

medicine.medical_specialtyatherogenic lipoproteins cardiovascular events atherosclerosisbusiness.industryInternal medicineInternal MedicinemedicineCardiologyIn patientGeneral MedicineAtherogenic lipoprotein phenotypeCardiology and Cardiovascular MedicinebusinessAtherosclerosis Supplements
researchProduct

Insulin resistance and familial dyslipidaemias

1999

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismHypercholesterolemiaHyperlipidemia Familial CombinedHyperlipidemiasLipid Metabolismmedicine.diseaseHyperlipoproteinemia Type IVEndocrinologyInsulin resistanceEndocrinologyInternal medicineInternal MedicinemedicineHumansInsulin ResistancebusinessDiabetes, Obesity and Metabolism
researchProduct

Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes

2011

Type 2 diabetes is associated with a cluster of inter-related plasma lipid and lipoprotein abnormalities, including reduced HDL-C, a predominance of small, dense LDL and elevated triglycerides. These abnormalities occur even in prediabetes, before blood sugars rise sufficiently in order to confirm a diagnosis of diabetes, and this transition phase incurs important cardiovascular risk. This is the rationale for paying attention to dyslipidemia through the use of the hypolipidemic, rather than hypoglycemic drugs only. A literature search (by Medline and Scopus) was performed. The authors also manually reviewed the references of selected articles for any pertinent material. Beyond the ‘quantit…

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentType 2 diabetesmedicine.diseaseMetformindiabetes LDL size prevention small dense LDL therapyEndocrinologyInternal medicineDiabetes mellitusmedicinelipids (amino acids peptides and proteins)PrediabetesCardiology and Cardiovascular MedicinebusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinClinical Lipidology
researchProduct

Lomitapide treatment highly affects lipoprotein profile and HDL functionality in patients with familial hypercholesterolemia

2015

medicine.medical_specialtybusiness.industryFamilial hypercholesterolemiamedicine.diseaseLomitapidechemistry.chemical_compoundEndocrinologychemistryInternal medicinemedicineIn patientHdl functionalityCardiology and Cardiovascular MedicinebusinessLipoproteinAtherosclerosis
researchProduct

Effects of statins on low-density-lipoproteins size: a new role in cardiovascular prevention ?

2006

Cardiovascular diseases still represent the first cause of death in most of the industrialized countries. An effective prevention includes the treatment of a series of risk factors: smoking, hypertension, diabetes, obesity and dyslipidemia.1 Statins represent a class of cholesterol-lowering drugs as inhibitors of the hydroxymethylglutaryl-coenzyme A reductase enzyme which catalyzes one of the first steps of the cholesterol metabolic pathway. This class of drugs has been used in a very large number of patients, in both primary and secondary cardiovascular prevention, for its ability to reduce clinical events linked to atherosclerosis, including acute myocardial infarction, unstable angina, c…

medicine.medical_specialtybusiness.industryGeneral MedicineLipoproteins LDLchemistry.chemical_compoundchemistryCardiovascular preventionCardiovascular DiseasesInternal medicineLow-density lipoproteinstatins low-density-lipoprotein cardiovascular preventionCardiologyMedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsParticle Sizebusiness
researchProduct